Trade Show

Orca Bio’s Orca-T® Meets Primary Endpoint in the Pivotal Precision-T Phase 3 Clinical Study for Hematologic Malignancies

ITNITN
MENLO PARK, Calif.–(BUSINESS WIRE)–Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.
0126
Previous Post
Next article
ITN
Today we live in a T-shaped world. While broad knowledge across the ecosystems is critical, deep insights and expertise of Subject Matter Experts help organizations leapfrog. At IndiaTechnologyNews, we cover much more than news, views and analysis, and we feature SMEs to help translate their knowledge to wider audiences. Reach me at editor@indiatechnologynews.in

You may also like

More in Trade Show